Relationships of Cotinine and Self-Reported Cigarette Smoking With Hemoglobin $A_{1c}$ in the U.S.

The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters

Citation

Published Version
doi:10.2337/dc11-0710

Citable link
http://nrs.harvard.edu/urn-3:HUL.InstRepos:10504379

Terms of Use
This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Relationships of Cotinine and Self-Reported Cigarette Smoking With Hemoglobin A₁c in the U.S.

Results from the National Health and Nutrition Examination Survey, 1999–2008

Carole Clair, MD¹
Asaf Bitton, MD, MPH²
James B. Meigs, MD, MPH³
Nancy A. Rigotti, MD¹

OBJECTIVE—Whether nicotine leads to a persistent increase in blood glucose levels is not clear. Our objective was to assess the relationship between cotinine, a nicotine metabolite, and glycated hemoglobin (HbA₁c), an index of recent glycemia.

RESEARCH DESIGN AND METHODS—We used cross-sectional data from the National Health and Nutrition Examination Survey (NHANES) from 1999 to 2008. We limited our analysis to 17,287 adults without diabetes. We created three cotinine categories: <0.05 ng/mL, 0.05–2.99 ng/mL, and ≥3 ng/mL.

RESULTS—Using self-report, 25% of the sample were current smokers, 24% were former smokers, and 51% were nonsmokers. Smokers had a higher mean HbA₁c (5.36%) compared with never smokers (5.34% ± 0.01) and former smokers (5.31% ± 0.01). In a similar manner, mean HbA₁c was higher among participants with cotinine ≥3 ng/mL (5.35% ± 0.01) and participants with cotinine 0.05–2.99 ng/mL (5.34% ± 0.01) compared with participants with cotinine <0.05 ng/mL (5.29% ± 0.01). In multivariable-adjusted analysis, we found that both a cotinine ≥3 ng/mL and self-reported smoking were associated with higher HbA₁c compared with a cotinine <0.05 ng/mL or not smoking. People with a cotinine level ≥3 ng/mL had a relative 5% increase in HbA₁c compared with people with a cotinine level <0.05 ng/mL, and smokers had a relative 7% increase in HbA₁c compared with never smokers.

CONCLUSIONS—Our study suggests that cotinine is associated with increased HbA₁c in a representative sample of the U.S. population without diabetes.

Diabetes Care 34:2250–2255, 2011

Cigarette smoking and type 2 diabetes are major public health burdens. Both are risk factors for cardiovascular disease and their co-occurrence has a dramatic impact on the absolute risk of mortality (1). Studies suggest that cigarette smoking is associated with an increased risk of developing type 2 diabetes (2).

The effects of smoking on risk of diabetes are commonly attributed to nicotine. In the short term, nicotine is known to cause elevations in blood glucose concentration (3). Whether this effect is transient or leads to persistent increase in blood glucose level is not clear. Several studies have shown that smoking is associated with increased levels of glycated hemoglobin (HbA₁c) (4–6), which is an objective index of chronic glycemia, but this relationship might be biased if smokers do not accurately report their smoking status. A more accurate assessment of the relationship between tobacco use and HbA₁c would be obtained by using a biologic marker for smoking, such as cotinine, the major proximate metabolite of nicotine. Two studies performed in populations with type 1 or type 2 diabetes have used cotinine (7,8), but to our knowledge, no study performed among people without diabetes has assessed systematically the relationship between HbA₁c and a biologic marker of nicotine exposure.

We used data from the National Health and Nutrition Examination Survey (NHANES) to assess the relationship between cotinine and HbA₁c among individuals with normal glucose metabolism and among people with impaired fasting glucose in subanalysis. Our hypothesis was that nicotine (using either blood cotinine or self-reported smoking status as a measure of nicotine exposure) is associated with higher HbA₁c in people without diabetes and in people in a prediabetic state.

RESEARCH DESIGN AND METHODS

Study sample
We analyzed data from NHANES, a nationally representative, cross-sectional survey that became a continuous biannual survey in 1999 (9). The continuous NHANES uses a complex stratified, multistage, cluster-sampling design to select a representative sample of the U.S. civilian noninstitutionalized population. We combined five successive waves (1999–2008) of the continuous NHANES for our analysis, producing a total sample of 51,623 people (Fig. 1). Participants answered a household interview and most completed clinical examinations in a mobile examination center. We limited the analysis to people who were both interviewed and examined, not pregnant, and ≥20 years old because the smoking questionnaire we used was administered to adults aged 20 years and older. We further excluded subjects...
with missing data on cotinine \((n = 1,589)\), HbA1c \((n = 1,271)\), education \((n = 44)\), waist circumference \((n = 1,290)\), diabetes status \((n = 13)\), smoking status \((n = 32)\), alcohol consumption \((n = 1,967)\), or physical activity \((n = 5)\). A total of 3,707 subjects \((14\%)\) were excluded because of missing values; compared with the nonexcluded participants, they were more likely to be female, black or Hispanic, smokers, and have a lower level of education and were less likely to be physically active. Excluded participants had slightly higher mean HbA1c \((5.6 \text{ vs. } 5.5\%, \text{ } P = 0.001)\) and lower waist circumference \((95.2 \text{ vs. } 97.1 \text{ cm}, \text{ } P < 0.0001)\), but their mean age and cotinine levels were similar to the nonexcluded participants. We limited our analyses to people without diabetes, excluding another 2,560 individuals. The NHANES protocol was approved by a human subjects review board, and informed consent was obtained from all participants.

### Smoking status

Smoking status was self-reported and was collected during the household interview of adults aged 20 years and older. Participants who reported smoking at least 100 cigarettes in their entire life and reporting that they did not smoke at all at the time of the interview were classified as current smokers. Participants who reported smoking fewer than 100 cigarettes during their lifetime were defined as former smokers. Participants who reported smoking at least 100 cigarettes in their entire life and reporting that they did not smoke at all at the time of the interview were classified as current smokers. Participants who reported smoking fewer than 100 cigarettes during their lifetime were defined as former smokers. This smoking definition has been widely used \((10)\) and classifies participants who have recently initiated smoking and very light smokers as never smokers.

### Cotinine

Cotinine is a major metabolite of nicotine that is used as a marker for active smoking and as an index of exposure to secondhand smoke \((11)\). Serum cotinine was measured using an isotope dilution–high performance liquid chromatography/atmospheric pressure chemical ionization tandem mass spectrometry \((12)\). The detection limits have changed over time in NHANES: in 1999–2000, it was 0.05 ng/mL; subsequently, it was lowered to 0.015 ng/mL. For consistency, we used the higher detection limit \((\text{cotinine} < 0.05 \text{ ng/mL})\). Participants below this threshold were classified as unexposed for all surveys as done in previous studies \((13)\). We created cotinine categories reflecting smoking exposures and used the cut point of 3 ng/mL recently proposed by Benowitz et al. \((14)\) to distinguish cigarette smokers and nonsmokers. We chose to use this new cut point rather than the older one \((14 \text{ ng/mL})\) because it is more sensitive and adapted to the current relatively low level of secondhand smoke exposure in the U.S. and it would pick up light or nondaily smokers. Our three categories of cotinine levels were 1) cotinine <0.05 ng/mL, 2) cotinine 0.05–2.99 ng/mL, and 3) cotinine ≥3 ng/mL.

### HbA1c and fasting plasma glucose

HbA1c was measured using a high performance liquid chromatography system. Fasting plasma glucose was measured in participants who were examined in the morning session after an 8- to 24-h fast \((\text{approximately half of the sample examined})\), using hexokinase enzymatic method.

### Diabetes

Diabetes was defined based on self-reported data and fasting glucose. People were considered to have diabetes if they had been told by a health professional that they had diabetes, if they reported taking insulin or diabetic pills to lower blood glucose, or if they had a fasting blood glucose ≥126 mg/dL.

---

**Figure 1**—Flowchart depicting five successive waves (1999–2008) of the continuous NHANES used for analysis. IFG, impaired fasting glucose.
Smoking, cotinine, and hemoglobin A₁c

(15), whether or not they reported having diabetes or being treated for diabetes. NHANES does not differentiate between type 1 and type 2 diabetes, but given the fact that we limited our analyses to participants without diabetes, it was not useful to make a distinction between them. Individuals were defined as having impaired fasting glucose if they had been told by a health professional that they were borderline for diabetes but did not take insulin or diabetic pills or if they had a fasting blood glucose ≥100 mg/dL and <126 mg/dL. The normal group consisted of participants who did report not having diabetes and who had a fasting blood glucose <100 mg/dL.

Other covariates
Demographic variables and information on alcohol consumption and physical activity were collected during the household interview. Race/ethnicity was categorized as non-Hispanic white, non-Hispanic black, Mexican American, other Hispanic, and other race. Alcohol consumption was categorized as 0, ≤1, 2–3, 4–5, and ≥6 drinks per week. For physical activity, we considered leisure time physical activity and categorized it in no or light, moderate, and vigorous. Weight and height were measured using standardized techniques and equipment during clinical examinations. BMI was calculated as weight in kilograms divided by height in meter squared. Waist circumference was measured at the uppermost lateral border of the ilium.

Statistical analysis
For all analyses, we accounted for the sampling design and used sample weights that account for unequal probabilities of selection and include adjustment for noncoverage and nonresponse. In univariate analysis, we calculated age-adjusted mean HbA₁c, according to cotinine and smoking status. To adjust for age, we used the direct method to the year 2000 census population projections using the age-groups 20–29, 30–39, 40–49, 50–59, 60–69, and 70 years and older. We built different linear regression models to assess the relationship between both cotinine and self-reported smoking categories and HbA₁c, the continuously distributed dependent variable. For each cotinine/smoking measure, we built two models. In the first model, we adjusted for age only. In the second model, we adjusted for age, sex, education, race/ethnicity, waist, alcohol consumption, and physical activity. Additional to the demographic variables, we chose to adjust for waist because it has been shown that smokers tend to have higher abdominal fat compared with never smokers (16) and abdominal fat is a good predictor of insulin resistance and, hence, higher HbA₁c (17). Moreover, it has been shown that smokers tend to have higher alcohol consumption and less physical activity compared with never smokers (18). Because these factors are also associated with diabetes and insulin resistance, we thought it was important to adjust for them in our analyses. We performed test for trend across categories of cotinine and across categories of self-reported smoking. These analyses were performed among participants without diabetes or impaired fasting glucose. In secondary analyses, we replicated these analyses among people with impaired fasting glucose. We also built logistic regression models with cotinine/smoking predicting high HbA₁c (>90th percentile). The cutoffs for high HbA₁c were 5.8 mg/dL for people without diabetes or impaired fasting glucose and 6.1 mg/dL for people with impaired fasting glucose. Again, we ran age- and multivariable-adjusted models. Finally, we explored if there was effect modification by age or ethnicity and performed stratified analyses for those two variables.

Statistical tests were two-sided and P < 0.025 was considered statistically significant, based on a Bonferroni correction for multiple testing of two different smoking exposure measures. We used SAS software version 9.2 (SAS Institute Inc., Cary, NC) and SUDAAN software version 10.0 (RTI, Research Triangle Park, NC) for our analysis.

RESULTS—After excluding people with diabetes, the final sample consisted of 17,287 people—14,096 without diabetes or impaired fasting glucose and 3,191 with impaired fasting glucose (Fig. 1).

Using self-report to identify smoking status, the sample included 4,073 smokers (25%), 4,377 former smokers (24%), and 8,837 never smokers (51%). Using cotinine levels, the sample included 4,991 participants with cotinine levels ≥3 ng/mL (30%), 4,946 participants with cotinine levels between 0.05 and 2.99 ng/mL (28%), and 7,350 participants with cotinine levels <0.05 ng/mL (42%). The majority of participants who reported themselves as smokers had cotinine levels ≥3 ng/mL (96%). Only 3% had cotinine levels between 0.05 and 2.99 ng/mL and <1% had cotinine levels <0.05 ng/mL. However, among those who self-reported themselves as nonsmokers (either never smokers or former smokers), 9% had cotinine levels ≥3 ng/mL and 36% had cotinine levels between 0.05 and 2.9 ng/mL.

Characteristics of participants are shown in Table 1. Self-reported smokers and participants with a cotinine level ≥3 ng/mL were more likely to be younger, male, have lower education, consume more alcohol, and have low level of physical activity compared with self-reported nonsmokers or participants with a cotinine level <0.05 ng/mL.

Mean age-adjusted HbA₁c according to cotinine and self-reported smoking status are shown in Table 2. Among people without diabetes or impaired fasting glucose, mean age-adjusted HbA₁c was slightly higher in participants with cotinine ≥3 ng/mL and participants with cotinine 0.05–2.99 ng/mL compared with participants with cotinine <0.05 ng/mL, with a significant trend across nicotine exposure categories suggesting a dose-response phenomenon. When we repeated the analysis among people with impaired fasting glucose, we also found that HbA₁c increased with nicotine exposure, but the trend was not significant. We did the same comparison according to self-reported smoking status and found similar results, with smokers having a higher mean HbA₁c compared with never smokers and former smokers.

In the linear regression models (Table 3), we found that cotinine ≥3 ng/mL and smoking were associated with higher HbA₁c compared with cotinine <0.05 ng/mL or not smoking. People with a cotinine level ≥3 ng/mL had a 5% increase in HbA₁c compared with people with a cotinine level <0.05 ng/mL, and smokers had a 7% increase in HbA₁c compared with never smokers in multivariable-adjusted analyses. P for trend across cotinine categories or self-reported smoking categories was significant and suggested a dose-response relationship. Subanalyses among people with impaired fasting glucose were similar. The stratified analyses for sex and ethnicity suggested an effect modification by sex (among males, smokers had an 11% increase in HbA₁c compared with never smokers) and ethnicity (among non-Hispanic whites, smokers had an 8% increase in HbA₁c compared with never smokers).

In the logistic regression models, among people without diabetes or impaired fasting glucose, we found in multivariable-adjusted analyses that participants with cotinine >3 ng/mL had 31% increased odds of elevated HbA₁c (HbA₁c ≥5.8%) compared with participants with cotinine
Table 1—Characteristics of participants ≥20 years old without diabetes, according to cotinine levels and self-reported smoking status in NHANES 1999–2008

<table>
<thead>
<tr>
<th>Cotinine category</th>
<th>Self-reported smoking status</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;0.05 ng/mL (n = 7,350)</td>
<td>Nonsmoker (n = 8,837)</td>
</tr>
<tr>
<td>0.05–2.99 ng/mL (n = 4,946)</td>
<td>44.6 ± 0.32</td>
</tr>
<tr>
<td>≥3 ng/mL (n = 4,991)</td>
<td>5,140 (57.6)</td>
</tr>
</tbody>
</table>

Data are mean ± SE. *Lower interquartile range (IQR) not calculable because of truncated data.

levels <0.05 ng/mL. Smokers had 37% increased odds of elevated HbA1c compared with nonsmokers (Supplementary Table 1).

CONCLUSIONS—In the current study, we used recent data representative of the U.S. population to show that both cotinine and self-reported smoking are associated with an increase in HbA1c in a population without diabetes and in people with impaired fasting glucose. Our analysis showed a relative increase in HbA1c of 5% for people with cotinine levels ≥3 ng/mL compared with people with cotinine levels <0.05 ng/mL. This would correspond to an absolute increase in HbA1c of 0.3%, for example, for someone with an HbA1c of 6.0%. Our findings support the hypothesis that smoking, and more specifically nicotine, leads to a persistent increase in blood glucose levels; however, it does not prove causality because of its cross-sectional design. Studies have shown that even a small increase in HbA1c concentrations has an impact on cardiovascular disease risk and mortality and that at a population level, an absolute reduction of just 0.1% HbA1c might reduce total mortality by 5–10% (19).

According to our data, 9% of people who reported being nonsmokers (never or former smokers) had cotinine levels ≥3 ng/mL, and 36% had cotinine levels between 0.05 and 2.9 ng/mL. This can be a consequence of either inaccurate reporting, use of nicotine replacement therapy, or exposure to secondhand smoke. Self-reported smoking has been evaluated as valid in NHANES in a study that took into account use of nicotine replacement therapy and exposure to secondhand smoke (20). Therefore, in our analyses,
Table 3—Association of HbA1c with cotinine levels and with self-reported smoking status among people in NHANES 1999-2008

<table>
<thead>
<tr>
<th>Cotinine categories</th>
<th>Age adjusted</th>
<th>Multivariable adjusted*</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>β Coefficient ± SE</td>
<td>P for trend</td>
</tr>
<tr>
<td>People without diabetes or IFG</td>
<td>&lt;0.0001</td>
<td>0.0002</td>
</tr>
<tr>
<td>&lt;0.05 ng/mL</td>
<td>(Ref)</td>
<td>(Ref)</td>
</tr>
<tr>
<td>0.05-2.99 ng/mL</td>
<td>0.05 ± 0.01</td>
<td>0.01 ± 0.01</td>
</tr>
<tr>
<td>≥3 ng/mL</td>
<td>0.06 ± 0.01</td>
<td>0.05 ± 0.01</td>
</tr>
<tr>
<td>People with IFG</td>
<td>0.027</td>
<td>0.008</td>
</tr>
<tr>
<td>&lt;0.05 ng/mL</td>
<td>(Ref)</td>
<td>(Ref)</td>
</tr>
<tr>
<td>0.05-2.99 ng/mL</td>
<td>0.02 ± 0.02</td>
<td>−0.00 ± 0.02</td>
</tr>
<tr>
<td>≥3 ng/mL</td>
<td>0.04 ± 0.02</td>
<td>0.05 ± 0.02</td>
</tr>
<tr>
<td>Self-reported smoking status</td>
<td>&lt;0.0001</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>People without diabetes or IFG</td>
<td>Non-smokers (Ref)</td>
<td>0.36</td>
</tr>
<tr>
<td></td>
<td>Smokers</td>
<td>0.03 ± 0.02</td>
</tr>
<tr>
<td>Former smokers</td>
<td>−0.00 ± 0.01</td>
<td>0.01 ± 0.01</td>
</tr>
<tr>
<td>Smokers</td>
<td>0.05 ± 0.01</td>
<td>0.07 ± 0.01</td>
</tr>
<tr>
<td>People with IFG</td>
<td>0.04 ± 0.02</td>
<td>0.00 ± 0.02</td>
</tr>
<tr>
<td>Nonsmokers</td>
<td>(Ref)</td>
<td>(Ref)</td>
</tr>
<tr>
<td>Former smokers</td>
<td>−0.04 ± 0.02</td>
<td>0.00 ± 0.02</td>
</tr>
</tbody>
</table>

P for trend: for trend across cotinine categories or self-reported smoking status, a Bonferroni-corrected α-level of P < 0.025 was considered statistically significant. IFG, impaired fasting glucose. Ref, reference group. *Adjusted for age (continuous), sex, education, race/ethnicity, waist (continuous), alcohol consumption (0, 1, 2, 3, 4, 5, or ≥6 drinks per week), and physical activity (none or light, moderate, vigorous).

because <0.2% of the nonsmokers used nicotine replacement therapy, we can consider the group with cotinine between 0.05 and 2.9 ng/mL as exposed to secondhand smoke. In this group, we observed a small increase in HbA1c levels. Our findings suggest that people with secondhand smoke exposure should get adequate attention because they might also have metabolic consequences as a result of their passive smoke exposure.

The association we have found between self-reported smoking and HbA1c is consistent with other cross-sectional studies (4–6). None of these studies used a biochemical marker such as cotinine to assess smoking exposure. They were performed in smaller samples, mainly in Europe, and consisted of a predominantly white population. Therefore, their results might not necessarily have been generalized to a U.S. multiethnic population.

The fact that cotinine is associated with higher HbA1c suggests that the relationship between smoking and HbA1c is at least partly related to effects of nicotine. Indeed, studies have shown that nicotine not only has a direct toxic effect on pancreatic β-cells (21) but also is associated with increased insulin resistance (22). Furthermore, the antiestrogenic effect of nicotine could contribute to an increase in visceral adipose tissue accumulation (23) and via this mechanism, insulin resistance. Finally, nicotine increases cortisol level (24) and inflammation and has an influence on adiponectin or peptides that regulate food intake and body weight, all of which could contribute to higher HbA1c.

Our study has several strengths. First, we tested the relationship between smoking and glycaemia using biochemically measured markers such as cotinine and HbA1c, rather than relying on self-reported smoking as has been done in the prior studies on this question. Second, it was conducted in a nationally representative sample; therefore, results may be generalized to the entire nondiabetic U.S. population. Finally, we adjusted for many possible confounders of the relationship between smoking and HbA1c.

Our study has several limitations. No inferences can be made on causality because of the cross-sectional design of the study. Even though we have adjusted for many potential confounders, we cannot exclude residual confounding or reverse causation. Finally, the half-life of nicotine varies between and within individuals, and a single measure of cotinine might not necessarily reflect chronic nicotine exposure over time.

In conclusion, our study suggests that smoking is associated with an increase in HbA1c in a representative sample of the U.S. population with normal glucose metabolism as well as in people with impaired fasting glucose. The dose-response phenomenon suggests that there might be a linear relationship between cotinine and HbA1c. These results support, but do not prove, the hypothesis that smoking, and more specifically nicotine, leads to a persistent increase in blood glucose levels.

Acknowledgments—C.C. has received grants from the Swiss National Science Foundation (PBLAP3-127728/1) and the SICPA Foundation. J.B.M. has received a grant from the National Institute of Diabetes and Digestive and Kidney Diseases (K24-DR-080140). N.A.R. has received a grant from the National Heart, Lung, and Blood Institute (K24-HL-04440). N.A.R. has consulted without pay for Pfizer and Free and Clear, Inc. about smoking cessation and has conducted research projects sponsored by Pfizer and Nabi Biopharmaceuticals. No other potential conflicts of interest relevant to this article were reported.

C.C. led analyses of data and statistical analyses and wrote the manuscript. A.B. assisted with interpretation of data and reviewed the manuscript. J.B.M. and N.A.R. interpreted data and wrote and reviewed the manuscript. Parts of this study were presented in abstract form at the 33rd Annual Meeting of the Society of General Internal Medicine, Minneapolis, Minnesota, 28 April–1 May 2010.

References


